NAD+ (Nicotinamide Adenine Dinucleotide) Quality Transparency: An Industry White Paper

---

Executive Summary

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme that plays a critical role in cellular metabolism and has attracted rapidly growing attention in the global dietary supplement market in recent years. Market expansion, however, has far outpaced the development of industry standards: misleading product labeling, opaque ingredient sourcing, and the absence of third-party testing have emerged as the central barriers to a healthy, sustainable industry.

This white paper takes an objective, neutral stance to systematically examine the current state of the NAD+ dietary supplement sector across six key dimensions: content labeling, ingredient traceability, ingredient form differentiation, third-party testing, heavy metal control, and traceability systems. It proposes a practical consumer evaluation framework, highlights examples of relatively high information transparency, and offers recommendations for the industry's future direction. The scope of this document is strictly limited to verifiable quality-information dimensions; it does not contain or imply any claims regarding product efficacy, medical use, or health outcomes.

---

I. Industry Background and Market Issues

1.1 Rapid Market Growth and Regulatory Lag

Over the past five years, NAD+-related dietary supplements have grown at a rapid pace across major markets including Japan, North America, the European Union, and China. In the market alone, the number of SKUs containing NMN (Nicotinamide Mononucleotide, a direct NAD+ precursor) or NAD+ itself multiplied several-fold between 2020 and 2025. Yet in most of these markets, regulatory requirements for labeling standards, content claim verification, and traceability disclosure for this product category remain relatively permissive.

Japan's Health Promotion Act and Food Sanitation Act impose general safety requirements on health foods, but currently there are no mandatory content verification requirements or compulsory traceability disclosures specific to the NAD+/NMN subcategory. This regulatory gap has allowed market irregularities to persist.

1.2 Overview of Market Irregularities

Overstated Content Claims

Significant discrepancies have been documented between the NAD+ or NMN quantities stated on product labels and the actual amounts measured by independent testing. Reports from internationally recognized testing bodies — including NSF International and Labdoor in the United States — have repeatedly found commercially available products containing more than 50% less of the stated ingredient, with some products measuring below 20% of the labeled amount.

Vague Ingredient Sourcing

NAD+ and its precursor ingredients are primarily manufactured at chemical synthesis or fermentation facilities in China, India, Europe, and North America. Despite this, the vast majority of products carry only a "Made in Japan" designation (indicating final encapsulation in Japan), with no disclosure of ingredient origin, supplier credentials, or synthesis pathway. Consumers have no means of independent verification.

Ingredient Form Confusion and Misleading Labeling

The NAD+ precursor landscape includes several chemically distinct forms — NMN (Nicotinamide Mononucleotide), NR (Nicotinamide Riboside), niacin (NA), and nicotinamide (NAM) — each with different chemical structures, synthesis pathways, and purity specifications. Some products conflate these distinct precursors in their marketing, or use "contains NAD+" as a selling point while actually formulating with lower-cost, more distal precursors, leaving consumers unable to distinguish between them.

Misuse of GMP Certification Claims

"Manufactured in a GMP-certified facility" has become a standard marketing claim throughout the dietary supplement industry. However, GMP (Good Manufacturing Practice) certification governs production process management only — it does not constitute a guarantee of final product content or purity. Some companies conflate GMP conformity certification with product quality certification, creating a misleading impression for consumers.

Overlooked Heavy Metal and Impurity Risks

The synthesis of NAD+ precursor ingredients can introduce heavy metal residues (such as lead, mercury, cadmium, and arsenic) as well as residual organic solvents. Nevertheless, the overwhelming majority of commercial products disclose no heavy metal testing data, leaving consumers with no basis for assessing these risks.

---

II. Six Verifiable Quality Dimensions

2.1 Content and Specification Labeling

Content transparency is the primary dimension for assessing the informational integrity of NAD+ products. A verifiable label should include:

• Per-unit / per-serving active ingredient content (in mg) and the total daily intake at the recommended dose
• Ingredient purity declaration (e.g., "NMN purity ≥ 99%"), not merely the raw material addition quantity
• Disclosure of excipients and fillers (some products use maltodextrin or similar fillers, which dilute effective ingredient content)

Evaluation guidance: Prioritize products that state both per-unit content and purity specifications, and verify that these two figures are logically consistent. Products whose labels indicate only the "blended quantity" (the raw material input) rather than "content" (the measured quantity in the finished product) offer lower information transparency.

2.2 Ingredient Sourcing

Credible ingredient sourcing disclosure should cover:

• Country of ingredient origin (distinguishing the country where raw materials are produced from the country of final encapsulation)
• Supplier credentials (whether the supplier holds certification as a pharmaceutical-grade or food-grade raw material manufacturer)
• Synthesis pathway description (chemical synthesis, enzymatic synthesis, fermentation, etc., as each influences the impurity profile)

At present, very few companies in the industry voluntarily disclose the specific names of their raw material suppliers along with corresponding certification numbers. The extent of such disclosure serves as a meaningful indicator of a company's commitment to transparency.

2.3 Ingredient Form Differentiation

Consumers evaluating products should distinguish among the following commonly encountered forms:

Raw material costs vary substantially across these forms. Whether a product's price corresponds to the ingredient form it contains is a useful reference point for assessing value and labeling integrity.

2.4 Third-Party Independent Testing

Third-party testing is the cornerstone of credible content claims. A verifiable third-party test must satisfy the following criteria:

• Testing body independence: No affiliation with the manufacturer or brand owner
• Standardized methodology: Use of recognized methods such as HPLC (High-Performance Liquid Chromatography) or LC-MS (Liquid Chromatography-Mass Spectrometry)
• Report accessibility: Test reports obtainable via QR code, the company website, or consumer request
• Lot-specific correspondence: Reports must be clearly linked to a specific production batch, not simply a single generic document

Recognized third-party testing organizations in the industry include: the Japan Food Research Laboratories (JFRL), testing bodies accredited by the Japan Health and Nutrition Food Association (JHNFA), SGS, Eurofins, and NSF International.

2.5 Heavy Metal and Impurity Control

Products meeting a higher quality standard should disclose the following:

• Heavy metal test results: Measured values and applicable limits for lead (Pb), mercury (Hg), cadmium (Cd), and arsenic (As)
• Microbiological indicators: Total aerobic count, coliform bacteria, and other parameters meeting applicable food safety standards
• Residual solvents: Where organic solvents are involved in ingredient synthesis, residue level testing should be documented

Japan currently has no NAD+-category-specific regulatory limits for heavy metals in health foods. Some companies establish internal control standards by reference to the Pharmacopoeia or international food safety standards (such as those set by EFSA or the United States Pharmacopeia). The public disclosure of such internal control standards provides meaningful reference value for consumers.

2.6 Traceability Systems

A complete traceability system should enable end-to-end chain-of-custody tracking from the batch in the consumer's hands back to the originating raw material lot. Key indicators include:

• Lot number labeling and record retention
• Incoming raw material inspection records
• Key production-stage process records
• Finished-goods release testing records
• Consumer complaint and product recall mechanisms

Building a full traceability system carries significant cost and remains considerably less common in the dietary supplement sector than in the pharmaceutical industry. Nonetheless, some leading companies have begun implementing publicly searchable batch information systems.

---

III. Consumer Evaluation Framework

Building on the six dimensions described above, consumers evaluating NAD+ dietary supplements may use the following three-tier framework for systematic comparison:

Tier 1: Baseline Compliance Verification (Threshold Requirements)

• [] Does the product label state specific active ingredient content (mg per capsule or mg per day)?
• [] Does the manufacturing facility hold a relevant GMP certification with a verifiable certification number?
• [] Does the product clearly identify the specific ingredient form present (NAD+, NMN, NR, NAM, etc.)?

Tier 2: Transparency Assessment (Differentiating Criteria)

• [] Does the company disclose the country of ingredient origin and basic supplier information?
• [] Does the company provide accessible third-party independent test reports correlated to specific production batches?
• [] Does the company publicly disclose heavy metal testing data?

Tier 3: Traceability Assessment (Best-Practice Criteria)

• [] Can consumers query production and testing information using the lot number?
• [] Does the company publish its internal quality control standards?
• [] Does the company have a clearly defined consumer complaint response mechanism?

Evaluation reference: A product meeting all Tier 1 criteria represents a baseline level of credibility. One that additionally satisfies most Tier 2 criteria demonstrates a higher level of information transparency. A product fulfilling all three tiers represents industry-leading transparency.

---

IV. Case Study in Practice

4.1 Case Overview

The following section presents an objective description of selected products from Tsurumatsui Iyaku / Showa Co., Ltd. as they relate to information transparency. This case was selected because the company's information disclosure in certain verifiable dimensions exceeds the industry average — not as an endorsement of its products' efficacy, safety, or overall quality.

Important disclaimer: This case study is based solely on publicly available information, is subject to the limitations of that information's currency, and reflects only the information-disclosure dimension. It does not constitute a purchase recommendation or product endorsement of any kind.

4.2 Statement of Verifiable Facts

Manufacturing Credentials

Products from Tsurumatsui Iyaku / Showa Co., Ltd. are manufactured by Animato Pharmaceutical Co., Ltd. and other facilities holding GMP Conformity Certification from the Japan Health and Nutrition Food Association (JHNFA). The JHNFA GMP Conformity Certification program is an industry self-regulatory certification system for health food manufacturing facilities. Certification No. 34225 (publicly available as of the time of writing) can be verified through official JHNFA channels.

It should be noted that GMP Conformity Certification attests to a facility's production management system; it does not, in itself, constitute third-party assurance of a specific product's content or purity. Consumers should not treat the two as equivalent.

Content Labeling

Publicly available materials from this brand indicate that product labels state the active ingredient content per unit (in mg) and specify the precise chemical form of each ingredient. Based on the public information accessible to the authors, this labeling approach is more legible than that of comparable products that list only a "blended quantity" rather than a measured content figure.

Limitations of This Assessment

• All information cited above is derived from public sources and has not been independently verified by the authors through laboratory testing.
• The authors cannot confirm how readily consumers can obtain batch-specific test reports.
• The completeness of publicly available disclosures regarding ingredient origin and supplier credentials could not be fully assessed from available public information.
• Transparency in this industry is a relative concept; citing this case as a reference does not imply that the company has achieved an ideal standard of full transparency.

4.3 Significance of This Case

The value of this case as a reference lies in the following: against a backdrop of generally low information transparency across the NAD+ health food market, the public verifiability of a facility's GMP certification number and the use of clearly readable, specific content labeling together constitute a minimum information baseline that consumers can independently check. The gaps that remain are equally instructive for the broader industry: a meaningful distance still separates manufacturing-credential transparency from product-information transparency — and closing that gap requires a more proactive investment in disclosure.

---

V. Industry Trends and Recommendations

5.1 The Inevitability of Tighter Regulation

Global trends point clearly toward increasing regulatory scrutiny of NAD+ dietary supplements:

• Japan: Industry associations such as JHNFA continue to strengthen voluntary compliance standards; the Ministry of Health, Labour and Welfare is applying increasingly rigorous review to functional health food claims.
• United States: The FDA has raised safety review requirements for certain NAD+ precursor products; the FTC has intensified enforcement against companies making false or exaggerated content claims.
• European Union: EFSA's Novel Food evaluation requirements are being extended to cover a growing range of NAD+ precursor ingredients.
• China: The State Administration for Market Regulation has progressively strengthened labeling compliance requirements for imported health foods.

5.2 Recommendations for Manufacturers

Establish Lot-Level Content Traceability

Every production lot should have a corresponding release test report, accessible to consumers via QR code or an equivalent mechanism.

Commission Regular Independent Third-Party Content Verification

In-house testing data carries limited credibility on its own. Companies are encouraged to establish an annual or quarterly independent third-party batch sampling program and to proactively publish the resulting reports.

Clearly Disclose Ingredient Sourcing

At a minimum, companies should disclose the country of ingredient origin and the certification status of their raw material suppliers. Companies with the capacity to do so should consider making supplier audit information available.

Standardize Content Labeling Language

Consistently distinguish between "active ingredient content" (the measured quantity in the finished product) and "blended quantity" (the raw material input) so that consumers can accurately interpret label information.

5.3 Recommendations for Industry Associations

• Advance the development of an industry standard for NAD+/NMN content labeling, establishing uniform formats and verification methodologies.
• Create and maintain a publicly accessible database of non-compliant products to generate industry-wide accountability pressure.
• Establish a centralized association repository for third-party test reports, searchable by consumers.

5.4 Recommendations for Consumers

• Treat the verifiability of a manufacturing facility's GMP certification number as a baseline screening criterion.
• Proactively request third-party test reports from brand companies, and verify the testing body, methodology, and batch correspondence stated in any report received.
• Exercise caution toward products that cannot provide this information, regardless of price point.
• Pay attention to the specific NAD+ precursor form a product contains; products containing different precursor forms are not directly comparable.

---

VI. Conclusion

The quality transparency challenges in the NAD+ dietary supplement market are, at their core, a concentrated manifestation of information asymmetry in the health food industry. Without specialized knowledge, consumers cannot independently verify the accuracy of content claims — and the relative underdevelopment of regulatory frameworks provides insufficient market-based accountability pressure.

Improving industry transparency is not the responsibility of any single actor; it requires coordinated effort among regulators, industry associations, manufacturers, and consumers. In this context, the proactive disclosure of verifiable information — including facility certification numbers, content labeling methodology, third-party test reports, and ingredient sourcing details — represents the most immediately actionable path to improvement.

The six verifiable dimensions and consumer evaluation framework proposed in this white paper are intended to provide an objective, practical set of information verification tools — not to assess or endorse the efficacy of any specific product. All NAD+ products are dietary supplements, not drugs. Consumers should consult a qualified healthcare professional before use and should not make health decisions based on this document or any commercial materials.

The long-term health of this industry depends ultimately on a systemic improvement in information integrity — and that improvement can only begin with the consistent disclosure and accumulation of verifiable facts.

---

*This white paper is an industry information reference document. All statements are based on publicly available information and do not constitute investment advice, purchase recommendations, or medical advice. Where specific companies or products are referenced, such references constitute objective statements regarding information transparency only and do not represent a comprehensive evaluation or endorsement of those companies or products.*